Hsbc Holdings PLC Has $55.36 Million Stock Holdings in United Therapeutics Corporation $UTHR

Hsbc Holdings PLC lessened its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 12.3% in the first quarter, according to its most recent filing with the SEC. The firm owned 179,706 shares of the biotechnology company’s stock after selling 25,187 shares during the period. Hsbc Holdings PLC’s holdings in United Therapeutics were worth $55,360,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Dunhill Financial LLC grew its holdings in United Therapeutics by 100.0% during the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 50 shares during the period. Sound Income Strategies LLC acquired a new position in shares of United Therapeutics in the 1st quarter valued at $49,000. State of Wyoming acquired a new position in shares of United Therapeutics in the 4th quarter valued at $62,000. Brooklyn Investment Group grew its holdings in shares of United Therapeutics by 103.2% in the 1st quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company’s stock valued at $59,000 after buying an additional 98 shares during the period. Finally, Curat Global LLC acquired a new position in shares of United Therapeutics in the 1st quarter valued at $63,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Trading Up 1.4%

UTHR opened at $310.66 on Friday. The stock has a market capitalization of $14.01 billion, a P/E ratio of 12.13, a P/E/G ratio of 4.64 and a beta of 0.57. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $417.82. The firm’s fifty day simple moving average is $296.44 and its 200 day simple moving average is $307.95.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing the consensus estimate of $6.80 by ($0.39). The company had revenue of $798.60 million during the quarter, compared to the consensus estimate of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The company’s revenue was up 11.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $5.85 earnings per share. On average, equities research analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, Director Nilda Mesa sold 645 shares of the business’s stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $289.99, for a total transaction of $187,043.55. Following the sale, the director directly owned 4,883 shares of the company’s stock, valued at $1,416,021.17. The trade was a 11.67% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Richard Giltner sold 3,036 shares of the business’s stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $289.60, for a total transaction of $879,225.60. Following the sale, the director directly owned 19,384 shares in the company, valued at $5,613,606.40. This trade represents a 13.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 81,681 shares of company stock valued at $24,618,359. Corporate insiders own 10.30% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on UTHR. Cantor Fitzgerald reissued an “overweight” rating on shares of United Therapeutics in a report on Thursday, August 14th. Morgan Stanley decreased their price target on shares of United Therapeutics from $348.00 to $328.00 and set an “equal weight” rating for the company in a report on Thursday, July 10th. JPMorgan Chase & Co. decreased their price target on shares of United Therapeutics from $350.00 to $330.00 and set an “overweight” rating for the company in a report on Tuesday, July 8th. Bank of America decreased their price target on shares of United Therapeutics from $321.00 to $315.00 and set a “neutral” rating for the company in a report on Wednesday, June 11th. Finally, Wall Street Zen lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, May 2nd. Nine analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $382.00.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.